{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:52Z","timestamp":1760909272965,"version":"3.37.3"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20H080002"],"award-info":[{"award-number":["LY20H080002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y20180218"],"award-info":[{"award-number":["Y20180218"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2019KY452"],"award-info":[{"award-number":["2019KY452"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is considered one of the most aggressive lymphoid tumors. However, it sometimes displays indolent behavior in patients and might not necessitate treatment at diagnosis; this has been described as \u201csmoldering MCL\u201d (SMCL). There are significant differences in the diagnosis, prognosis, molecular mechanisms and treatments of indolent MCL and classical MCL. In this review, we discuss the progress in understanding the molecular mechanism of indolent MCL to provide insights into the genomic nature of this entity. Reported findings of molecular features of indolent MCL include a low Ki-67 index, CD200 positivity, a low frequency of mutations in TP53, a lack of SOX11, normal arrangement and expression of MYC, IGHV mutations, differences from classical MCL by L-MCL16 assays and MCL35 assays, an unmutated P16 status, few defects in ATM, no NOTCH1\/2 mutation, Amp 11q gene mutation, no chr9 deletion, microRNA upregulation\/downregulation, and low expression of several genes that have been valued in recent years (SPEN, SMARCA4, RANBP2, KMT2C, NSD2, CARD11, FBXW7, BIRC3, KMT2D, CELSR3, TRAF2, MAP3K14, HNRNPH1, Del 9p and\/or Del 9q, SP140 and PCDH10). Based on the above molecular characteristics, we may distinguish indolent MCL from classical MCL. If so, indolent MCL will not be overtreated, whereas the treatment of classical MCL will not be delayed.<\/jats:p>","DOI":"10.1186\/s40164-021-00232-3","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:03:26Z","timestamp":1626181406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Progress in molecular feature of smoldering mantle cell lymphoma"],"prefix":"10.1186","volume":"10","author":[{"given":"Panruo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-1322","authenticated-orcid":false,"given":"Haige","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"232_CR1","doi-asserted-by":"crossref","unstructured":"Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020.","DOI":"10.1182\/blood.2020005289"},{"issue":"13","key":"232_CR2","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927\u201338.","journal-title":"Blood Adv"},{"issue":"4","key":"232_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","volume":"70","author":"V Fernandez","year":"2010","unstructured":"Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408\u201318.","journal-title":"Cancer Res"},{"issue":"4","key":"232_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","volume":"132","author":"G Clot","year":"2018","unstructured":"Clot G, Jares P, Gine E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4):413\u201322.","journal-title":"Blood"},{"issue":"1(No.2120)","key":"232_CR5","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/cancers12082120","volume":"12","author":"D Malarikova","year":"2020","unstructured":"Malarikova D, Berkova A, Obr A, et al. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers. 2020;12(1(No.2120)):2120.","journal-title":"Cancers."},{"key":"232_CR6","doi-asserted-by":"crossref","unstructured":"Hsi, Eric, D., et al. Indolent mantle cell lymphoma. Leukemia Lymphoma. 2014.","DOI":"10.3109\/10428194.2013.815353"},{"key":"232_CR7","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. 2017;Volume 2."},{"issue":"15","key":"232_CR8","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1200\/JCO.2010.31.8006","volume":"29","author":"SA Rule","year":"2011","unstructured":"Rule SA, Poplar S, Evans PA, et al. Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol. 2011;29(15):e437\u20139.","journal-title":"J Clin Oncol"},{"key":"232_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","volume":"41","author":"A Sakhdari","year":"2019","unstructured":"Sakhdari A, Ok CY, Patel KP, et al. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019;41:38\u201342.","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"232_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/modpathol.2017.135","volume":"31","author":"Z Hu","year":"2018","unstructured":"Hu Z, Sun Y, Schlette EJ, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018;31(2):327\u201336.","journal-title":"Mod Pathol"},{"key":"232_CR11","doi-asserted-by":"crossref","unstructured":"S C, M P, Ajm F, et al. Mantle cell lymphoma. Critical reviews in oncology\/hematology. 2020;153:103038.","DOI":"10.1016\/j.critrevonc.2020.103038"},{"issue":"9","key":"232_CR12","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","volume":"28","author":"BS Dabaja","year":"2017","unstructured":"Dabaja BS, Zelenetz AD, Ng AK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28(9):2185\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"232_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00277-019-03803-x","volume":"99","author":"JC Jo","year":"2020","unstructured":"Jo JC, Kim SJ, Lee HS, et al. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: consortium for improving survival of lymphoma report. Ann Hematol. 2020;99(2):223\u20138.","journal-title":"Ann Hematol"},{"issue":"4","key":"232_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/bjh.15519","volume":"184","author":"H Rauert-Wunderlich","year":"2019","unstructured":"Rauert-Wunderlich H, Mottok A, Scott DW, et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br J Haematol. 2019;184(4):616\u201324.","journal-title":"Br J Haematol"},{"issue":"9","key":"232_CR15","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/j.1349-7006.2011.01988.x","volume":"102","author":"Y Kimura","year":"2011","unstructured":"Kimura Y, Sato K, Imamura Y, et al. Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. Cancer Sci. 2011;102(9):1734\u201341.","journal-title":"Cancer Sci"},{"issue":"1","key":"232_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","volume":"36","author":"H Ye","year":"2017","unstructured":"Ye H, Desai A, Zeng D, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"232_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1078-0432.CCR-13-1077","volume":"20","author":"B Espinet","year":"2014","unstructured":"Espinet B, Ferrer A, Bellosillo B, et al. Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry. Clin Cancer Res. 2014;20(4):1007\u201319.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"232_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806\u201313.","journal-title":"Am J Hematol"},{"key":"232_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-14-153","volume":"14","author":"X He","year":"2014","unstructured":"He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153.","journal-title":"BMC Cancer"},{"issue":"6","key":"232_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-016-2016-8","volume":"469","author":"M Gallo","year":"2016","unstructured":"Gallo M, Cacheux V, Vincent L, et al. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch. 2016;469(6):697\u2013706.","journal-title":"Virchows Arch"},{"issue":"12","key":"232_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386\u201394.","journal-title":"J Clin Oncol"},{"issue":"4","key":"232_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.prp.2018.02.015","volume":"214","author":"W Hou","year":"2018","unstructured":"Hou W, Wei P, Xie J, et al. The degree of overlap between the follicular dendritic cell meshwork and tumor cells in mantle cell lymphoma is associated with prognosis. Pathol Res Practice. 2018;214(4):513\u201320.","journal-title":"Pathol Res Practice"},{"issue":"18","key":"232_CR23","first-page":"3318","volume":"119","author":"ZI Chakhachiro","year":"2013","unstructured":"Chakhachiro ZI, Saliba RM, Okoroji G, et al. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer-Am Cancer Soc. 2013;119(18):3318\u201325.","journal-title":"Cancer-Am Cancer Soc"},{"key":"232_CR24","doi-asserted-by":"crossref","unstructured":"Medani H, Elshiekh M, Naresh KN. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. J Clin Pathol. 2020:2020\u2013206956.","DOI":"10.1136\/jclinpath-2020-206956"},{"issue":"8","key":"232_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.bjc.6602795","volume":"93","author":"C Schrader","year":"2005","unstructured":"Schrader C, Janssen D, Klapper W, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93(8):939\u201345.","journal-title":"Br J Cancer"},{"issue":"2","key":"232_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/his.12009","volume":"62","author":"N Vogt","year":"2013","unstructured":"Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology. 2013;62(2):334\u201342.","journal-title":"Histopathology"},{"issue":"5","key":"232_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/ijlh.12857","volume":"40","author":"YS Ting","year":"2018","unstructured":"Ting YS, Smith SABC, Brown DA, et al. CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. Int J Lab Hematol. 2018;40(5):533\u20139.","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"232_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1309\/AJCPBV9ELXC0ECVL","volume":"142","author":"P Challagundla","year":"2014","unstructured":"Challagundla P, Medeiros LJ, Kanagal-Shamanna R, et al. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142(6):837\u201344.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"232_CR29","doi-asserted-by":"publisher","first-page":"13551","DOI":"10.18632\/oncotarget.6948","volume":"7","author":"Y Miao","year":"2016","unstructured":"Miao Y, Fan L, Wu Y, et al. Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. Oncotarget. 2016;7(12):13551\u201362.","journal-title":"Oncotarget"},{"issue":"5","key":"232_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cyto.b.21849","volume":"98","author":"M Sorigue","year":"2020","unstructured":"Sorigue M, Magnano L, Miljkovic MD, et al. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2020;98(5):441\u20138.","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"232_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/PAS.0000000000001233","volume":"43","author":"J Xu","year":"2019","unstructured":"Xu J, Wang L, Li J, et al. SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients. Am J Surg Pathol. 2019;43(5):710\u20136.","journal-title":"Am J Surg Pathol"},{"key":"232_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humpath.2019.04.010","volume":"89","author":"A Saksena","year":"2019","unstructured":"Saksena A, Yin CC, Xu J, et al. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum Pathol. 2019;89:71\u201380.","journal-title":"Hum Pathol"},{"key":"232_CR33","doi-asserted-by":"crossref","unstructured":"Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia\/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. J Clin Exp Hematop. 2020.","DOI":"10.3960\/jslrt.19041"},{"issue":"4","key":"232_CR34","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3892\/or.2017.5891","volume":"38","author":"L Zlamalikova","year":"2017","unstructured":"Zlamalikova L, Moulis M, Ravcukova B, et al. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Oncol Rep. 2017;38(4):2535\u201342.","journal-title":"Oncol Rep"},{"issue":"6","key":"232_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/emmm.201200229","volume":"4","author":"CT Williamson","year":"2012","unstructured":"Williamson CT, Kubota E, Hamill JD, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. Embo Mol Med. 2012;4(6):515\u201327.","journal-title":"Embo Mol Med"},{"issue":"3","key":"232_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/iub.2453","volume":"73","author":"A Almeida","year":"2021","unstructured":"Almeida A, S\u00e1nchez Mor\u00e1n I, Rodr\u00edguez C. Mitochondrial\u2013nuclear p53 trafficking controls neuronal susceptibility in stroke. IUBMB Life. 2021;73(3):582\u201391.","journal-title":"IUBMB Life"},{"key":"232_CR37","doi-asserted-by":"crossref","unstructured":"Obr A, Klener P, Furst T, et al. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Brit J Haematol. 2020.","DOI":"10.1111\/bjh.17063"},{"issue":"6","key":"232_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-017-0598-1","volume":"19","author":"S Bea","year":"2017","unstructured":"Bea S, Amador V. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. Curr Oncol Rep. 2017;19(6):43.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"232_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00277-013-1783-4","volume":"92","author":"D Caballero","year":"2013","unstructured":"Caballero D, Campo E, Lopez-Guillermo A, et al. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma Recommendations from the GEL\/TAMO Spanish Cooperative Group. Ann Hematol. 2013;92(9):1151\u201379.","journal-title":"Ann Hematol"},{"issue":"3","key":"232_CR40","first-page":"699","volume":"36","author":"L Stefancikova","year":"2010","unstructured":"Stefancikova L, Moulis M, Fabian P, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol. 2010;36(3):699\u2013706.","journal-title":"Int J Oncol"},{"issue":"8","key":"232_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/gcc.22849","volume":"59","author":"L Streich","year":"2020","unstructured":"Streich L, Sukhanova M, Lu X, et al. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020;59(8):484\u201394.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"232_CR42","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1007\/s12032-011-0096-5","volume":"29","author":"H Dong","year":"2012","unstructured":"Dong H, Zhou L, Fang C, et al. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. Med Oncol. 2012;29(3):2166\u201373.","journal-title":"Med Oncol"},{"issue":"17","key":"232_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310.","journal-title":"Blood"},{"key":"232_CR44","first-page":"9185432","volume":"2020","author":"RK Mccall","year":"2020","unstructured":"Mccall RK, Pang CS, Pettenati MJ. Non-Nodal CD5-Negative mantle cell lymphoma with secondary TP53 Deletion. Case Rep Hematol. 2020;2020:9185432.","journal-title":"Case Rep Hematol"},{"issue":"4","key":"232_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417\u201320.","journal-title":"Blood"},{"key":"232_CR46","doi-asserted-by":"crossref","unstructured":"Pararajalingam P, Coyle KM, Arthur S, et al. Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020.","DOI":"10.1101\/686956"},{"key":"232_CR47","doi-asserted-by":"crossref","unstructured":"Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Brit J Haematol. 2018.","DOI":"10.1111\/bjh.15721"},{"issue":"8","key":"232_CR48","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","volume":"96","author":"SL Ondrejka","year":"2011","unstructured":"Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121\u20137.","journal-title":"Haematologica"},{"key":"232_CR49","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/srep01400","volume":"3","author":"AM Wasik","year":"2013","unstructured":"Wasik AM, Lord M, Wang X, et al. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep. 2013;3:1400.","journal-title":"Sci Rep"},{"issue":"3","key":"232_CR50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3324\/haematol.2019.219543","volume":"105","author":"B Federmann","year":"2020","unstructured":"Federmann B, Frauenfeld L, Pertsch H, et al. Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. Haematologica. 2020;105(3):754\u201364.","journal-title":"Haematologica"},{"issue":"4","key":"232_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor \u00c1, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130(4):501\u201313.","journal-title":"Blood"},{"issue":"5","key":"232_CR52","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3109\/10428194.2014.953147","volume":"56","author":"AM Wasik","year":"2015","unstructured":"Wasik AM, Priebe V, Lord M, et al. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma from mantle cell lymphoma. Leuk Lymphoma. 2015;56(5):1425\u201331.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"232_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2018-05-851667","volume":"133","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Sandoval N, Phan A, et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019;133(4):306\u201318.","journal-title":"Blood"},{"issue":"2","key":"232_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.15582","volume":"184","author":"E Cencini","year":"2019","unstructured":"Cencini E, Sicuranza A, Fabbri A, et al. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol. 2019;184(2):223\u201331.","journal-title":"Br J Haematol"},{"issue":"1","key":"232_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","volume":"13","author":"DH Yoon","year":"2020","unstructured":"Yoon DH, Cao J, Chen TY, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol. 2020;13(1):21.","journal-title":"J Hematol Oncol"},{"key":"232_CR56","doi-asserted-by":"crossref","unstructured":"Yang R, Huo Z, Duan Y, et al. SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma. Leuk Lymphoma. 2020:1\u201314.","DOI":"10.1080\/10428194.2020.1762877"},{"issue":"20","key":"232_CR57","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307\u201316.","journal-title":"Cancer Res"},{"issue":"1","key":"232_CR58","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.12854","volume":"166","author":"L Nordstrom","year":"2014","unstructured":"Nordstrom L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma\u2013a Nordic Lymphoma Group study. Br J Haematol. 2014;166(1):98\u2013108.","journal-title":"Br J Haematol"},{"issue":"3","key":"232_CR59","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.tranon.2020.100744","volume":"13","author":"T Annese","year":"2020","unstructured":"Annese T, Ingravallo G, Tamma R, et al. Inflammatory infiltrate and angiogenesis in mantle cell lymphoma. Transl Oncol. 2020;13(3):100744.","journal-title":"Transl Oncol"},{"key":"232_CR60","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Hassan M, Freiburghaus C, et al. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol. 2020.","DOI":"10.1111\/bjh.17023"},{"issue":"3","key":"232_CR61","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00428-015-1840-6","volume":"468","author":"B Sander","year":"2016","unstructured":"Sander B, Quintanilla-Martinez L, Ott G, et al. Mantle cell lymphoma\u2013a spectrum from indolent to aggressive disease. Virchows Arch. 2016;468(3):245\u201357.","journal-title":"Virchows Arch"},{"issue":"10","key":"232_CR62","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416\u201323.","journal-title":"J Clin Invest"},{"issue":"4","key":"232_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MOH.0000000000000434","volume":"25","author":"R Beekman","year":"2018","unstructured":"Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018;25(4):299\u2013306.","journal-title":"Curr Opin Hematol"},{"key":"232_CR64","doi-asserted-by":"crossref","unstructured":"Kiel MJ, Smith LB. Transformation of Indolent Mantle Cell Lymphoma to Pleomorphic Mantle Cell Lymphoma: Case Report and Review of Clinical and Morphologic Variants. Arch Pathol Lab Med. 2012;(No.8):871\u2013875.","DOI":"10.5858\/arpa.2012-0197-CR"},{"issue":"8","key":"232_CR65","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3109\/10428194.2015.1121257","volume":"57","author":"V Kuci","year":"2016","unstructured":"Kuci V, Nordstrom L, Conrotto P, et al. SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma. Leuk Lymphoma. 2016;57(8):1883\u201392.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"232_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","volume":"124","author":"VH van der Velden","year":"2014","unstructured":"van der Velden VH, Hoogeveen PG, de Ridder D, et al. B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood. 2014;124(3):412\u20139.","journal-title":"Blood"},{"key":"232_CR67","unstructured":"Wang L, Tang G, Medeiros LJ, et al. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica (Roma). 2020."},{"issue":"4","key":"232_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/genes8040116","volume":"8","author":"L Nguyen","year":"2017","unstructured":"Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes-Basel. 2017;8(4):116.","journal-title":"Genes-Basel"},{"issue":"6","key":"232_CR69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2141.2009.07791.x","volume":"146","author":"F Jardin","year":"2009","unstructured":"Jardin F, Picquenot J, Parmentier F, et al. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. Brit J Haematol. 2009;146(6):607\u201318.","journal-title":"Brit J Haematol"},{"key":"232_CR70","doi-asserted-by":"crossref","unstructured":"Scapinello G, Riva M, Branca A, et al. A case of \u201cdouble hit\u201d mantle cell lymphoma carrying CCND1 and MYC translocations relapsed\/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. Ann Hematol. 2020.","DOI":"10.1007\/s00277-020-04178-0"},{"issue":"2","key":"232_CR71","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PAS.0000000000000758","volume":"41","author":"Z Hu","year":"2017","unstructured":"Hu Z, Medeiros LJ, Chen Z, et al. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. Am J Surg Pathol. 2017;41(2):216.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"232_CR72","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/his.12760","volume":"68","author":"J Choe","year":"2016","unstructured":"Choe J, Yun JY, Na HY, et al. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. Histopathology. 2016;68(3):442\u20139.","journal-title":"Histopathology"},{"issue":"12","key":"232_CR73","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1158\/1078-0432.CCR-12-3077","volume":"19","author":"A Navarro","year":"2013","unstructured":"Navarro A, Clot G, Prieto M, et al. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res. 2013;19(12):3121\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"232_CR74","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975\u201381.","journal-title":"Blood"},{"issue":"22","key":"232_CR75","doi-asserted-by":"publisher","first-page":"e15811","DOI":"10.1097\/MD.0000000000015811","volume":"98","author":"X Li","year":"2019","unstructured":"Li X, Wu N, Li B. A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients. Medicine. 2019;98(22):e15811.","journal-title":"Medicine."},{"issue":"15","key":"232_CR76","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","volume":"35","author":"DW Scott","year":"2017","unstructured":"Scott DW, Abrisqueta P, Wright GW, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35(15):1668\u201377.","journal-title":"J Clin Oncol"},{"issue":"2","key":"232_CR77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bjh.15518","volume":"183","author":"H Holte","year":"2018","unstructured":"Holte H, Beiske K, Boyle M, et al. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Br J Haematol. 2018;183(2):225\u201334.","journal-title":"Br J Haematol"},{"issue":"11","key":"232_CR78","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","volume":"105","author":"F Rubio-Moscardo","year":"2005","unstructured":"Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105(11):4445\u201354.","journal-title":"Blood"},{"issue":"1","key":"232_CR79","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4161\/cc.4.1.1337","volume":"4","author":"BT Spike","year":"2005","unstructured":"Spike BT, Macleod KF. The Rb tumor suppressor in stress responses and hematopoietic homeostasis. Cell Cycle. 2005;4(1):42\u20135.","journal-title":"Cell Cycle"},{"issue":"5","key":"232_CR80","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"M Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604\u201311.","journal-title":"Blood"},{"issue":"8","key":"232_CR81","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1080\/1042819021000002884","volume":"43","author":"T Stankovic","year":"2009","unstructured":"Stankovic T, Stewart GS, Byrd P, et al. ATM mutations in sporadic lymphoid tumours. Leukemia Lymphoma. 2009;43(8):1563\u201371.","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"232_CR82","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","volume":"60","author":"A Mareckova","year":"2019","unstructured":"Mareckova A, Malcikova J, Tom N, et al. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leukemia Lymphoma. 2019;60(6):1420\u20138.","journal-title":"Leukemia Lymphoma"},{"issue":"9","key":"232_CR83","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1073\/pnas.0831102100","volume":"100","author":"F Ny","year":"2003","unstructured":"Ny F, Tc G, Dd W, et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci. 2003;100(9):5372\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"45","key":"232_CR84","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci. 2013;110(45):18250\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"232_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1748-717X-1-35","volume":"1","author":"AR Filippi","year":"2006","unstructured":"Filippi AR, Franco P, Galliano M, et al. Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiation Oncol (London, England). 2006;1(1):35.","journal-title":"Radiation Oncol (London, England)"},{"issue":"6","key":"232_CR86","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","volume":"4","author":"P Jain","year":"2020","unstructured":"Jain P, Zhang S, Kanagal-Shamanna R, et al. Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020;4(6):1038\u201350.","journal-title":"Blood Adv"},{"issue":"1","key":"232_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ajcp\/aqz133","volume":"153","author":"J Zhou","year":"2020","unstructured":"Zhou J, Hu L, Zuo M, et al. An uncommon case of double-hit mantle cell lymphoma that demonstrates a transformation process. Am J Clin Pathol. 2020;153(1):49\u201357.","journal-title":"Am J Clin Pathol"},{"issue":"19","key":"232_CR88","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988\u201396.","journal-title":"Blood"},{"issue":"6","key":"232_CR89","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623\u20139.","journal-title":"Am J Hematol"},{"issue":"4","key":"232_CR90","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Brit J Haematol. 2018;183(4):578\u201387.","journal-title":"Brit J Haematol"},{"issue":"5\u20136","key":"232_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","volume":"25","author":"P Yang","year":"2018","unstructured":"Yang P, Zhang W, Wang J, et al. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5\u20136):129\u201340.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"232_CR92","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105(6):1604\u201312.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"232_CR93","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-139955","volume":"136","author":"Y Yan","year":"2020","unstructured":"Yan Y, Yi S, Jin M, et al. Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma. Blood. 2020;136(Supplement 1):28\u20139.","journal-title":"Blood"},{"issue":"1","key":"232_CR94","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan Y, Tam CS, et al. Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119\u201329.","journal-title":"Nat Med"},{"issue":"25","key":"232_CR95","doi-asserted-by":"publisher","first-page":"38180","DOI":"10.18632\/oncotarget.9500","volume":"7","author":"C Wu","year":"2016","unstructured":"Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180\u201390.","journal-title":"Oncotarget"},{"issue":"8","key":"232_CR96","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3324\/haematol.2011.047357","volume":"96","author":"M Furtado","year":"2011","unstructured":"Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica. 2011;96(8):1086\u20138.","journal-title":"Haematologica"},{"issue":"10","key":"232_CR97","first-page":"1019","volume":"85","author":"M Martini","year":"2000","unstructured":"Martini M, D\u2019Alo F, Pierconti F, et al. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. Haematologica. 2000;85(10):1019\u201323.","journal-title":"Haematologica"},{"issue":"3","key":"232_CR98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0145-2126(03)00255-8","volume":"28","author":"BD Hock","year":"2004","unstructured":"Hock BD, Haring LF, Steinkasserer A, et al. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leukemia Res. 2004;28(3):237\u201341.","journal-title":"Leukemia Res"},{"key":"232_CR99","doi-asserted-by":"crossref","unstructured":"Ziduo Li EAKL. Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. Clinical & translational immunology. 2020;9(7).","DOI":"10.1002\/cti2.1156"},{"issue":"3","key":"232_CR100","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2011.04.001","volume":"48","author":"A Navarro","year":"2011","unstructured":"Navarro A, Royo C, Hernandez L, et al. Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. Semin Hematol. 2011;48(3):155\u201365.","journal-title":"Semin Hematol"},{"issue":"2","key":"232_CR101","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12185-017-2236-y","volume":"106","author":"W Yang","year":"2017","unstructured":"Yang W, Wang Y, Yu Z, et al. SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. Int J Hematol. 2017;106(2):212\u201320.","journal-title":"Int J Hematol"},{"issue":"4","key":"232_CR102","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/hon.2106","volume":"32","author":"YW Koh","year":"2014","unstructured":"Koh YW, Shin S, Park C, et al. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages. Hematol Oncol. 2014;32(4):178\u201386.","journal-title":"Hematol Oncol"},{"issue":"5","key":"232_CR103","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","volume":"34","author":"P Jain","year":"2020","unstructured":"Jain P, Wang M. Blastoid Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020;34(5):941\u201356.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"21","key":"232_CR104","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1182\/blood-2011-07-370122","volume":"119","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood. 2012;119(21):4939\u201348.","journal-title":"Blood"},{"issue":"4","key":"232_CR105","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.bbrc.2018.12.055","volume":"508","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wang J, Zhu M, et al. MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7 H3. Biochem Bioph Res Co. 2019;508(4):1067\u201373.","journal-title":"Biochem Bioph Res Co"},{"key":"232_CR106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exphem.2017.10.005","volume":"58","author":"K Zhou","year":"2018","unstructured":"Zhou K, Feng X, Wang Y, et al. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. Exp Hematol. 2018;58:27\u201334.","journal-title":"Exp Hematol"},{"key":"232_CR107","doi-asserted-by":"crossref","unstructured":"H Y, J T, Jq C, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood: The Journal of the American Society of Hematology. 2010;(13):2630\u20132639.","DOI":"10.1182\/blood-2009-09-243147"},{"issue":"23","key":"232_CR108","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2012.45.3050","volume":"31","author":"RS Goswami","year":"2013","unstructured":"Goswami RS, Atenafu EG, Xuan Y, et al. MicroRNA signature obtained from the comparison of aggressive with indolent non-hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013;31(23):2903\u201311.","journal-title":"J Clin Oncol"},{"key":"232_CR109","doi-asserted-by":"crossref","unstructured":"Wu B, Li J, Wang H, et al. MiR-132\u20133p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. Naunyn-Schmiedeberg's Archives of Pharmacology. 2020.","DOI":"10.1007\/s00210-020-01834-0"},{"issue":"6","key":"232_CR110","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3109\/10428194.2011.642303","volume":"53","author":"K Zhou","year":"2012","unstructured":"Zhou K, Yi S, Yu Z, et al. MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leukemia Lymphoma. 2012;53(6):1155\u201361.","journal-title":"Leukemia Lymphoma"},{"issue":"17","key":"232_CR111","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","volume":"125","author":"S Husby","year":"2015","unstructured":"Husby S, Ralfkiaer U, Garde C, et al. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood. 2015;125(17):2669\u201377.","journal-title":"Blood"},{"issue":"6","key":"232_CR112","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/gcc.22355","volume":"55","author":"A Roisman","year":"2016","unstructured":"Roisman A, Huam\u00e1n Garaicoa F, Metrebian F, et al. SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. Genes Chromosom Cancer. 2016;55(6):531\u201340.","journal-title":"Genes Chromosom Cancer"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-021-00232-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-021-00232-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-021-00232-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:18:22Z","timestamp":1699229902000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-021-00232-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1186\/s40164-021-00232-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"type":"electronic","value":"2162-3619"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}